Long-term expression of human growth hormone (hGH) in mice containing allogeneic yolk sac cell derived neovascular implants expressing hGH

Stem Cells

Volumn 14, Issue 2, 1996, Pages 232-238

  Wei, Yanzhang ^a   Li, Jinhua ^a   Wagner, Thomas E ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

Allogeneic mice; Gene delivery; Gene therapy; Human growth hormone; Rat anti mouse B7.2 antibody; Yolk sac cell

Indexed keywords

CD86 ANTIGEN; GENE PRODUCT; HUMAN GROWTH HORMONE;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTER; GENE TARGETING; GENE THERAPY; MOUSE; NONHUMAN; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; YOLK SAC;

ANIMALIA; MURINAE;

EID: 0030010106     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140232     Document Type: Article

References (26)

1. St. Louis D, Verma IM. An alternative approach to somatic cell gene therapy. Proc Natl Acad Sci USA 1988;85:3150-3154.
2. Palmer TD, Rosman GJ, Osborne WRA et al. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 1991;88.1330-1334.
3. Fenjves ES, Gordon DA, Pershing LK et al. Systemic distribution of apolipoprotein E secreted by grafts of epidermal keraunocytes: implication for epidermal function and gene therapy. Proc Natl Acad Sci USA 1989;86:8803-8807.
4. Morgan JR, Barrandon Y, Green H et al. Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science 1987;237:1476-1479.
5. Gerrard AJ, Hudson DL, Brownlee GG et al. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993;3:180-183.
6. Smith GH, Gallahan D, Zwiebel JA et al. Long-term in vivo expression of genes introduced by retrovirus-mediated transfer into mammary epithelial cells. J Virol 1991;65:6365-6370.
7. Zwiebel JA, Freeman SM, Kantoff PW et al. High level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. Science 1989;243:220-243.
8. Dai Y, Roman M, Naviaux RK et al. Gene therapy via primary myoblasts long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992;89:10892-10895.
9. Lynch CM, Clowes MM, Osborne WRA et al. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. Proc Natl Acad Sci USA 1992;89:1138-1142.
10. Yao SN, Karachi K. Expression of human factor IX in mice after injection of genetically modified myoblast. Proc Natl Acad Sci USA 1992;89:3357-3361.
11. Wei YZ, Quertermous T, Wagner TE. Directed endothelial differentiation of cultured embryonic yolk sac cells in vivo provides a novel cell-based system for gene therapy. STEM CELLS 1995;13:541-547.
12. Jenkins MK, Taylor PS, Norton SD et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-2466.
13. June CH, Ledbetter JA, Linsley PS et al. Role of the CD28 receptor in T-cell activation. Immunol Today 1990;11:211-216.
14. Reiser H, Freeman GJ, Razi-Wolf Z et al. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992;89:271-275.
15. + T lymphocytes. J Immunol 1992;148:1985-1992.
16. Harding FA, McArthur JG, Gross JA et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-609.
17. Lenschow DJ, Zeng Y, Thistlethwaite JR et al Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
18. Palis J, McGrath KE, Kingsley PD. Initiation of hematopoiesis and vasculogenesis in murine yolk sac explants. Blood 1995;86:156-163.
19. Barut BA, Antczak M, Winnard A et al. Isolation and characterization of endothelial cell lines from murine yolk sac. Blood 1994;84(suppl 1):74.
20. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology, 2nd ed. Philadelphia, PA: W.B. Saunders Company, 1994:163-164.
21. Freeman GJ, Borriello F, Hodes RJ et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993;262:907-909.
22. Freeman GJ, Gribben JG, Boussiotis VA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
23. Kay MA, Holterman AX, Meuse L et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995;11:191-197.
24. Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-795.
25. Hathcock KS, Laszlo G, Dickler HB et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993;262:905-907.
26. Heartlein MW, Roman VA, Jiang JL et al. Long-term production and delivery of human growth hormone in vivo. Proc Natl Acad Sci USA 1994;91:10967-10971.